Pfizer (PFE) Cash from Financing Activities (2009 - 2026)
Pfizer (PFE) reported Cash from Financing Activities of -$2.9 billion for Q1 2026, up 45.36% year-over-year from -$2.0 billion in Q1 2025, and down 579.19% on a QoQ basis from $596.0 million in Q4 2025.
Pfizer (PFE) has 18 years of Cash from Financing Activities data on file, last reported at -$2.9 billion in Q1 2026.
- Quarterly Cash from Financing Activities rose 45.36% year-over-year to -$2.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.9 billion (up 67.81% YoY) and the FY2025 annual result came in at -$10.3 billion, up 39.88% from the prior year.
- Cash from Financing Activities slipped to -$2.9 billion in Q1 2026 per PFE's latest filing, from $596.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $27.2 billion in Q3 2023 and bottomed at -$12.0 billion in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$2.9 billion (2026), against an average of -$1.4 billion.
- The widest annual swing landed in 2023, when Cash from Financing Activities jumped 978.33%; it then tumbled 218.23% in 2024.
- Tracing PFE's Cash from Financing Activities over 5 years: stood at -$9.8 billion in 2022, then surged by 155.42% to $5.4 billion in 2023, then tumbled by 320.98% to -$12.0 billion in 2024, then jumped by 104.96% to $596.0 million in 2025, then slumped by 579.19% to -$2.9 billion in 2026.
- Per Business Quant, the three latest PFE Cash from Financing Activities figures stand at -$2.9 billion (Q1 2026), $596.0 million (Q4 2025), and -$2.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -2.86 Bn |
| Mar 29, 2026 | -2.86 Bn |
| Dec 31, 2025 | 596.00 Mn |
| Dec 31, 2025 | 596.00 Mn |
| Sep 28, 2025 | -2.48 Bn |
| Sep 28, 2025 | -2.48 Bn |
| Jun 29, 2025 | -3.20 Bn |
| Jun 29, 2025 | -3.20 Bn |
| Mar 30, 2025 | -5.23 Bn |
| Mar 30, 2025 | -5.23 Bn |
| Sep 29, 2024 | -12.03 Bn |
| Sep 29, 2024 | -12.03 Bn |
| Jun 30, 2024 | -2.46 Bn |
| Jun 30, 2024 | -2.46 Bn |
| Mar 31, 2024 | -4.93 Bn |
| Mar 31, 2024 | -4.93 Bn |
| Dec 31, 2023 | 5.44 Bn |
| Dec 31, 2023 | 5.44 Bn |
| Oct 1, 2023 | -3.78 Bn |
| Oct 1, 2023 | -3.78 Bn |
| Jul 2, 2023 | 27.17 Bn |
| Jul 2, 2023 | 27.17 Bn |
| Apr 2, 2023 | -2.77 Bn |
| Apr 2, 2023 | -2.77 Bn |
| Oct 2, 2022 | -9.82 Bn |
| Oct 2, 2022 | -9.82 Bn |
| Jul 3, 2022 | 2.52 Bn |
| Jul 3, 2022 | 2.52 Bn |
| Apr 3, 2022 | -6.58 Bn |
| Apr 3, 2022 | -6.58 Bn |
| Oct 3, 2021 | -6.47 Bn |
| Oct 3, 2021 | -6.47 Bn |
| Jul 4, 2021 | -2.56 Bn |
| Jul 4, 2021 | -2.56 Bn |
| Apr 4, 2021 | -2.81 Bn |
| Apr 4, 2021 | -2.81 Bn |
| Sep 27, 2020 | -7.26 Bn |
| Sep 27, 2020 | -7.26 Bn |
| Jun 28, 2020 | 9.16 Bn |
| Jun 28, 2020 | 9.16 Bn |
| Mar 29, 2020 | -2.20 Bn |
| Mar 29, 2020 | -2.20 Bn |
| Dec 31, 2019 | -2.44 Bn |
| Dec 31, 2019 | -2.44 Bn |
| Sep 29, 2019 | 3.27 Bn |
| Sep 29, 2019 | 3.27 Bn |
| Jun 30, 2019 | -851.00 Mn |
| Jun 30, 2019 | -851.00 Mn |
| Mar 31, 2019 | -8.47 Bn |
| Mar 31, 2019 | -8.47 Bn |
| Dec 31, 2018 | -6.41 Bn |
| Dec 31, 2018 | -6.41 Bn |
| Sep 30, 2018 | -1.41 Bn |
| Sep 30, 2018 | -1.41 Bn |
| Jul 1, 2018 | -1.91 Bn |
| Jul 1, 2018 | -1.91 Bn |
| Apr 1, 2018 | -10.72 Bn |
| Apr 1, 2018 | -10.72 Bn |
| Dec 31, 2017 | -3.74 Bn |
| Dec 31, 2017 | -3.74 Bn |
| Oct 1, 2017 | -1.71 Bn |
| Oct 1, 2017 | -1.71 Bn |
| Jul 2, 2017 | -2.99 Bn |
| Jul 2, 2017 | -2.99 Bn |
| Apr 2, 2017 | -4.91 Bn |
| Apr 2, 2017 | -4.91 Bn |
| Dec 31, 2016 | -2.31 Bn |
| Dec 31, 2016 | -2.31 Bn |
| Oct 2, 2016 | -1.66 Bn |
| Oct 2, 2016 | -1.66 Bn |
| Jul 3, 2016 | 1.92 Bn |
| Jul 3, 2016 | 1.92 Bn |
| Apr 3, 2016 | -7.17 Bn |
| Apr 3, 2016 | -7.17 Bn |
| Dec 31, 2015 | -1.29 Bn |
| Dec 31, 2015 | -1.29 Bn |
| Sep 27, 2015 | -263.00 Mn |
| Sep 27, 2015 | -263.00 Mn |
| Jun 28, 2015 | -1.87 Bn |
| Jun 28, 2015 | -1.87 Bn |
| Mar 29, 2015 | -6.98 Bn |
| Mar 29, 2015 | -6.98 Bn |
| Dec 31, 2014 | -3.13 Bn |
| Dec 31, 2014 | -3.13 Bn |
| Sep 28, 2014 | -2.89 Bn |
| Sep 28, 2014 | -2.89 Bn |
| Jun 29, 2014 | -2.04 Bn |
| Jun 29, 2014 | -2.04 Bn |
| Mar 30, 2014 | -2.13 Bn |
| Mar 30, 2014 | -2.13 Bn |
| Dec 31, 2013 | -5.74 Bn |
| Dec 31, 2013 | -5.74 Bn |
| Sep 29, 2013 | -5.63 Bn |
| Sep 29, 2013 | -5.63 Bn |
| Jun 30, 2013 | -4.03 Bn |
| Jun 30, 2013 | -4.03 Bn |
| Mar 31, 2013 | 434.00 Mn |
| Mar 31, 2013 | 434.00 Mn |
| Dec 31, 2012 | -6.23 Bn |
| Dec 31, 2012 | -6.23 Bn |
| Sep 30, 2012 | -3.29 Bn |
| Sep 30, 2012 | -3.29 Bn |
| Jul 1, 2012 | -2.97 Bn |
| Jul 1, 2012 | -2.97 Bn |
| Apr 1, 2012 | -3.51 Bn |
| Apr 1, 2012 | -3.51 Bn |
| Dec 31, 2011 | -6.25 Bn |
| Dec 31, 2011 | -6.25 Bn |
| Oct 2, 2011 | -4.04 Bn |
| Oct 2, 2011 | -4.04 Bn |
| Jul 3, 2011 | -3.92 Bn |
| Jul 3, 2011 | -3.92 Bn |
| Apr 3, 2011 | -6.40 Bn |
| Apr 3, 2011 | -6.40 Bn |
| Dec 31, 2010 | -1.08 Bn |
| Dec 31, 2010 | -1.08 Bn |
| Oct 3, 2010 | -2.52 Bn |
| Oct 3, 2010 | -2.52 Bn |
| Jul 4, 2010 | -4.36 Bn |
| Jul 4, 2010 | -4.36 Bn |
| Apr 4, 2010 | -3.21 Bn |
| Apr 4, 2010 | -3.21 Bn |
| Dec 31, 2009 | -2.73 Bn |
| Dec 31, 2009 | -2.73 Bn |
| Sep 27, 2009 | -1.83 Bn |
| Sep 27, 2009 | -1.83 Bn |
| Jun 28, 2009 | 9.41 Bn |
| Jun 28, 2009 | 9.41 Bn |
| Mar 29, 2009 | 9.64 Bn |
| Mar 29, 2009 | 9.64 Bn |